Une équipe suédoise rétablit le contrôle de la glycémie chez des souris diabétiques

Des chercheurs en Suède ont créé des cellules productrices d'insuline à partir de cellules souches humaines, lesquelles ont permis d'inverser les symptômes du diabète après avoir été transplantées chez des souris. Les cellules ont mûri après leur implantation dans l'œil et ont assuré la régulation du glucose pendant plusieurs mois. Ces travaux ont été publiés dans la revue Stem Cell Reports.

Des scientifiques du Karolinska Institutet ont mis au point un protocole amélioré permettant de dériver des îlots pancréatiques à partir de multiples lignées de cellules souches pluripotentes humaines. Cette méthode utilise des conditions de culture affinées et des amas tridimensionnels afin de réduire les types cellulaires indésirables et d'améliorer la réponse au glucose.

Articles connexes

Scientists in a lab celebrating conditional approval of iPS cell products for treating Parkinson's and heart disease.
Image générée par IA

Health ministry panel conditionally approves iPS cell products

Rapporté par l'IA Image générée par IA

A health ministry expert panel has conditionally approved two regenerative medicine products derived from induced pluripotent stem (iPS) cells for treating Parkinson's disease and severe heart disease. This marks a potential world first in commercializing Nobel Prize-winning stem cell technology. The approval, based on small-scale clinical trials confirming safety and presumed efficacy, requires post-market verification within seven years.

A team led by Leonardo Ferreira at the Medical University of South Carolina is developing a novel therapy combining lab-made insulin-producing cells with engineered immune cells to protect them. Funded by $1 million from Breakthrough T1D, the approach aims to restore beta cell function without immunosuppressive drugs. This strategy builds on prior research and targets all stages of the disease.

Rapporté par l'IA

Researchers have identified why living at high altitudes reduces diabetes risk: red blood cells absorb excess glucose in low-oxygen conditions. This metabolic shift lowers blood sugar levels, as shown in mouse experiments. A new drug mimicking this effect reversed diabetes in mice, suggesting potential treatments.

Scientists have developed a hybrid obesity treatment that uses GLP-1 and GIP signals to deliver a metabolic enhancer directly into cells. Early tests in mice showed greater weight loss and better blood sugar control than standard therapies. The approach aims to reduce side effects by limiting the drug's action to targeted areas.

Rapporté par l'IA Vérifié par des faits

Researchers at the University of California, Riverside say they have developed a flexible, battery-powered gel patch that generates oxygen inside hard-to-heal wounds—an approach aimed at countering deep-tissue oxygen deprivation that can stall recovery and contribute to amputations. In experiments in diabetic and older mice, the team reported that wounds that often remained open—and were sometimes fatal—closed in about 23 days when treated with the oxygen-generating patch.

Ce site utilise des cookies

Nous utilisons des cookies pour l'analyse afin d'améliorer notre site. Lisez notre politique de confidentialité pour plus d'informations.
Refuser